LUND, SWEDEN--(Marketwire - Oct 19, 2012) - Active Biotech (NASDAQ OMX NORDIC: ACTI) today
announces that its partner Ipsen (Euronext: IPN; ADR: IPSEY, read press
here) will initiate a new phase II, proof-of-concept clinical trial
tasquinimod in a so-called umbrella study evaluating the compound in
different tumor types.
The study will evaluate the safety and efficacy of tasquinimod in
metastatic hepato-cellular, ovarian, renal cell and gastric
patients who have progressed after standard therapies.
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company
focus on autoimmune/inflammatory diseases and cancer. Projects in or
pivotal phase are laquinimod, an orally administered small molecule with
immunomodulatory properties for the treatment of multiple sclerosis,
for prostate cancer as well as ANYARA for use in cancer targeted
primarily of renal cell cancer. In addition, laquinimod is in
development for Crohn's and Lupus. An additional project in clinical
is the orally administered compound 57-57 for Systemic Sclerosis. Please
www.activebiotech.com for more information.
Active Biotech is obligated to publish the information contained in this
release in accordance with the Swedish Securities Market Act. This
was provided to the media for publication 7:00 a.m. CET on October 19,
Active Biotech's partner Ipsen initiates a proof-of-concept study :
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE